NCT05975021 - A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

July 28, 2025

Study Completion Date

August 31, 2026

Conditions

Cardiogenic Shock

Interventions

DRUG

Istaroxime

IV infusion via a syringe pump. Dosage of 1.0 µg/kg/min for 6 hours; 0.5 µg/kg/min for 42 hours. Total duration 48 hours.

DRUG

Placebo

IV infusion via a syringe pump. Total duration 48 hours.

Trial Locations (15)

1180

Sanatorio Güemes, Capital Federal

1425

Sanatorio De la Trinidad Palermo, Capital Federal

10123

University of Turin, Città della Salute e della Scienza, Turin

15121

Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria

20132

IRCCS San Raffaele Scientific Institute, Milan

25123

ASST degli Spedali Civili di Brescia, Brescia

76100

Kaplan Medical Center, Rehovot

97201

Oregon Health and Sciences University, Portland

02111

Tufts Medical Center, Boston

S2000DSR

Instituto Cardiovascular de Rosario, Rosario

S2000GAP

Hospital Privado de Rosario, Rosario

15-276

Uniwersytecki Szpital Kliniczny w Białymstoku, Bialystok

45-401

Uniwersytecki Szpital Kliniczny w Opolu, Opole

50-556

Uniwersytecki Szpital Kliniczny, Instytut Chorob Serca, Wroclaw

50-981

4 Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ, Wroclaw